LeMaitre Vascular Inc (NASDAQ: LMAT) has reported E.P.S. of $0.44 for its first fiscal quarter (ending March 31) versus $0.27 for the same period a year ago — an increase of 63%. Relative to the consensus estimate of $0.43, this was a premium of $0.01. E.P.S. were $1.52 for the latest four quarters through March 31 versus $0.94 for the same period a year ago — an increase of 62%.
Recent Price Action
On 5/2/24, LeMaitre Vascular Inc (NASDAQ: LMAT) stock declined slightly by -0.01%, closing at $66.77. Moreover, this decline was accompanied by above average trading volume at 135% of normal. Relative to the market the stock has been strong over the last nine months and has risen 4.3% during the last week.
Current PriceTarget Research Rating
LMAT’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be a Value Builder.
LeMaitre Vascular has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. LeMaitre Vascular has a poor Appreciation Score of 17 but a good Power Rating of 74, resulting in the Low Neutral Value Trend Rating.
Rating Review
In light of this encouraging new earnings information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment